Corbus Pharmaceuticals
Corbus Pharmaceuticals
CRBP
NASDAQ
16.57
USD
-5.58%
About
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells.
Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco.
The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 278.2K |
| Three Month Average Volume | 6.5M |
| High Low | |
| Fifty-Two Week High | 61.9 USD |
| Fifty-Two Week Low | 3.0334 USD |
| Fifty-Two Week High Date | 31 Jul 2024 |
| Fifty-Two Week Low Date | 13 Nov 2023 |
| Price and Volume | |
| Current Price | 61.18 USD |
| Beta | 3 |
| Relative Price Change | |
| Four Week Relative Price Change | 2.21% |
| Thirteen Week Relative Price Change | 33.56% |
| Twenty-Six Week Relative Price Change | 58.98% |
| Fifty-Two Week Relative Price Change | 568.82% |
| Year-to-Date Relative Price Change | 755.36% |
| Price Change | |
| One Day Price Change | 5.46% |
| Thirteen Week Price Change | 42.94% |
| Twenty-Six Week Price Change | 74.80% |
| Five Day Price Change | 2.48% |
| Fifty-Two Week Price Change | 738.08% |
| Year-to-Date Price Change | 912.91% |
| Month-to-Date Price Change | 2.88% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -1.56085 USD |
| Book Value Per Share (Most Recent Quarter) | 10.91781 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -1.56085 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 10.91781 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -5.60746 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -10.30679 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -5.82006 USD |
| Normalized (Last Fiscal Year) | -10.30679 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -10.30679 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -5.82006 USD |
| Including Extraordinary Items (Last Fiscal Year) | -10.30679 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -5.82006 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 4.72593 USD |
| Cash Per Share (Most Recent Quarter) | 12.78598 USD |
| Cash Flow Per Share (Last Fiscal Year) | -10.15866 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -4.8657 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -4.26699 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -660 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -769.76% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -832.02% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -769.76% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | 110.27% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 55.95% |
| EPS Change (Trailing Twelve Months) | 47.17% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | 6 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -136,204,000 |
| Net Debt (Last Fiscal Year) | -4,697,130 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | 6 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 6 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -36,100,470 |
| Free Cash Flow (Trailing Twelve Months) | -30,095,230 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -15 |
| Net Interest Coverage (Trailing Twelve Months) | -30 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | 9 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -94.31% |
| Return on Assets (Trailing Twelve Months) | -35.74% |
| Return on Assets (5 Year) | -86.84% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -341.98% |
| Return on Equity (Trailing Twelve Months) | -51.78% |
| Return on Equity (5 Year) | -192.45% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -178.23% |
| Return on Investment (Trailing Twelve Months) | -45.03% |
| Return on Investment (5 Year) | -130.46% |